Notes

Mechanochemically Lively Gentle Spiders.
Two new lanostane triterpnenoids named endertiins A and B (1 and 2) together with two known compounds as ganodecalone A (3) and ergosterol (4) have been successfully isolated from the cultivated fruit bodies of the mushroom Humphreya endertii Stey (Ganodermataceae). Their structures were elucidated by a combination of HR-MS and 2 D NMR spectroscopic analyses. In addition, endertiins A and B (1 and 2) were evaluated their cytotoxicity against two cancer cell lines, MCF7 (human breast carcinoma) and LU (human lung carcinoma). The result showed that endertiin A (1) could inhibit the growth of MCF-7 cells with its IC50 value of 71.16 ± 6.25 µg/ml.
To report the outcomes of a survey on patients' concerns and satisfaction with custom ocular prosthesis (COP) wear and compare with objective clinician grading scales.

The questionnaire was answered by 156 participants. General social concerns and prosthesis-related concerns were plotted on a scale of 0 to 10, indicating least to maximum satisfaction and also not concerned to very concerned. Comparison between subjective patient and objective clinician scores was done.

The mean age at presentation was 27.53 ± 15.53 years (range 3-72 years).For patients that underwent a prior surgical procedure, mean satisfaction with the surgery was 9.42 ± 1.27. Mean satisfaction with the COP was 8.98 ± 1.75. The median satisfaction score for the primary surgery as well as for the outcome of the custom ocular prosthesis was 10. Commonest prosthesis-related concerns were reduced motility (mean 3 ± 2, median 3), watering, crusting and discharge (mean 2 ± 2, median 2), and difference in the size of the prosthetic eye relative to the other eye (mean 1 ± 2, median 1). Subjective patient concern responses and the objective clinician grading correlated strongly for movement of the prosthesis (r = -0.84, p < .0001), periocular fullness (r = 0.65, p < .0001), color of the prosthesis (r = -0.8, p < .0001) and size relative to the other eye (r = 0.7, p < .0001).

Custom ocular prosthesis usage had a high satisfaction score with minimal concerns. Commonest prosthesis-related concerns correlated strongly with objective clinician grading.
Custom ocular prosthesis usage had a high satisfaction score with minimal concerns. Commonest prosthesis-related concerns correlated strongly with objective clinician grading.This is a narrative reflection about my experience of the ongoing coronavirus (COVID-19) outbreaks across countries between January and early March 2020. My recalled memories showed the shifting and contingent thoughts and emotions. Contextual factors such as my ethnic identity and local anti-coronavirus policies also constructed my perceptions of the pandemic. While my story is unfinished as the coronavirus outbreak is still happening, the narratives provide a novel perspective to understand public health practices in a global context. As the health knowledge construction is infused with identity and personal meanings, this reflection also shows that people from a racial group may face unfair treatment in a pandemic. My narratives suggest the need for a more globally synchronized health communication in pandemics.The study was intended to find in vitro antioxidant, cytotoxicity and safety profile of Polystichum braunii roots extracts and chemically characterise it by GC-MS and FTIR spectroscopy. Acute and sub-chronic (90-day oral repeated dose at 150, 300 and 600 mg/kg) toxicity studies of P. braunii methanol extract (PBME) were performed in Wistar rats by adopting OECD guidelines. The PBME exerted the highest in vitro antioxidant potential. There was no substantial change in blood parameters and body weight except a notable (p  less then  0.01) rise in ALT, ALP, MDA and HDL, and decrease in cholesterol and LDL (p  less then  0.05) in animals sub-chronically treated with PBME at 600 mg/kg dose. The IC50 in HepG2 was more than 1000 µg/ml. The GC-MS analysis revealed Pentadecanoic acid and 9,12-Octadecadienoic acid in PBME. The P. braunii might be safe in acute usage, however, monitoring of liver function tests should be carried out during long-term use.
Anti-PD-1/PD-L1-based therapy has emerged recently, and we aimed to figure out the latent value of different clinical and molecular factors to predict the efficacy of immune checkpoint inhibitors (ICIs) therapy compared with non-immunotherapy in the first-line setting.

We assessed the clinical outcomes of 8711 patients in 13 trials receiving anti-PD-1/PD-L1-based therapy or non-immunotherapy as first-line treatment, and different predictors were investigated.

Overall, compared with non-immunotherapy, anti-PD-1/PD-L1-based therapy reduced the risk of death by 31% (HR 0.69, 95%CI 0.60-0.79) for all cancers. Stratified analysis showed that the progression-free survival (PFS) benefit from anti-PD-1/PD-L1-based therapy existed in all three PD-L1 status subgroups (tumour proportion score, TPS ≥50% HR 0.54, 95%CI 0.38-0.78; TPS 1-49% HR 0.56, 95%CI 0.46-0.68; TPS <1% HR 0.82, 95%CI 0.73-0.91; interaction,
 < 0.01). ICI therapy also prolonged PFS in males (HR 0.64, 95%CI 0.50-0.83) and younger patients (HR 0.70, 95%CI 0.52-0.93), and they might prolong overall survival (OS) in patients without brain metastasis (HR 0.54, 95%CI 0.41-0.71).

PD-L1 expression level alone is imperfect to predict the efficacy of anti-PD-1/PD-L1-based therapies as first-line cancer treatment. Meanwhile, sex, age, and status of brain metastases might also be predictive parameters for the selection of cancer patients.
PD-L1 expression level alone is imperfect to predict the efficacy of anti-PD-1/PD-L1-based therapies as first-line cancer treatment. Meanwhile, sex, age, and status of brain metastases might also be predictive parameters for the selection of cancer patients.
Familial hypercholesterolemia (FH) is a genetic disease characterized by increased levels of low-density lipoprotein cholesterol (LDL-C). selleck inhibitor It is underdiagnosed and undertreated despite relatively high prevalance and significant association with increased mortality. We aimed to determine treatment status and compliance in patients with LDL-C≥250mg/dL and FH.

Patients older than 18years old and have a serum LDL-C≥250mg/dL between January 2010 to December 2016 were identified from the hospital database. A phone survey was performed. Demographic features, smoking status, alcohol use, exercise, cardiovascular disease (CVD), use of medication for dyslipidemia, and CVD and high cholesterol levels in the family were questioned. Dutch Lipid Clinical Network Criteria was used to classify patients. The study was registered to Clinicaltrials.gov in July 2020 (NCT04494464).

1365 patients with a LDL-C≥250mg/dL were identified. Patients that could not be reached and who refused to interview were excluded and the data of 367 patients were analyzed.
Website: https://www.selleckchem.com/